The latest breast cancer news from reliable sources can be found on the MediPaper website. Get an instant update with the latest developments in breast cancer.

Olaparib Under Review by EMA for BRCA-mutated, HER2-negative Breast Cancer

A marketing authorization application for olaparib (Lynparza) for the treatment of women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting has been accepted by the European Medicines Agency.

Read full article (External website)

EMA to Review Olaparib in BRCA-mutated, HER2-negative Breast Cancer

The European Medicines Agency has accepted a marketing authorization application for olaparib to treat women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

Read full article (External website)

AKT Inhibitor May Overcome Chemotherapy Resistance in 2 Breast Cancer Subtypes

A novel inhibitor that targets the AKT node in the PI3K pathway may offer a treatment option in cases of resistance to chemotherapy in 2 patient populations: triple-negative breast cancer or estrogen receptor

Read full article (External website)

Death due to cancer on the decline for most tumours in Europe

The exceptions are death due to lung and pancreatic carcinoma in women which are both still on the rise, according to a new study, published in Annals of Oncology on the 19th of March 2018.

Researchers predict that the death rates for most types of cancer will be lower in 2018 when compared to 2012 in the European Union.

The study, led by Carlo La Vecchia (MD) of the University of Milan, shows that death due to colorectal cancer (CRC) is on the decline in Europe. The researchers call the drop in death-rates of CRC, which is the most common cause of cancer-death in non-smoking males and females, one of the major achievements in the management of oncologic diseases over the recent years.

Key numbers for CRC:

  • CRC is the second highest cause of cancer-death: 177,400 (male: 98,000 in men; female 79,400);
  • Due to the ageing population, the absolute quantities of fatalities have risen since 2012;
  • In contrast, the age-standardised rates will decrease by 6.7% in men (15.8 per 100,000) and 7.5% in women (9.2 per 100,000).

Risk factors for CRC include:

  • Tobacco
  • Alcohol
  • Obesity
  • Diabetes
  • Sedentary lifestyle
  • Unhealthy diet

The use of oral contraceptives and hormone-replacement therapy in women may partly explain the decreased risk in females. Furthermore, the use of aspirin for prevention of cardiovascular disease and effective screening may further contribute to a decrease in the incidence of the disease in both sexes.

Key numbers for all cancers in Europe:

  • In 2018, 1.4 million cancer deaths are predicted, up from 1.3 million in 2012.
  • Death-rates have fallen by 10.3% in men and 5% in women
  • Age-standardised death rates in 2018 are predicted to be 130 per 100,000 for men and 84 per 100,000 for women.

Citations

  1. Malvezzi M et al. Ann Oncol. doi:10.1093/annonc/mdy033

Expert Highlights Current Advancements and Questions in Breast Cancer Treatment

Kornelia Polyak, MD, PhD, discusses several exciting advancements in the field of breast cancer, including immunotherapy, PARP inhibitors, and liquid biopsies.

Read full article (External website)

EMA Suggests Extension of Therapeutic Indications for Denosumab

Extension of indication includes the avoidance of skeletal-related events in grown-ups with late-stage malignancies involving the bone

On 22 February 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending towards a change in the marketing authorisation for denosumab (licensee: Amgen Europe BV).

The following extension of the label was adopted by the CHMP:

  • Prevention of skeletal-related events in adults with advanced malignancies involving bone (e.g. pathological fracture, radiation to the bone, spinal cord compression, or surgery to the bone).

Previously, denosumab was only indicated for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

Reference:
http://www.esmo.org/Oncology-Information/EMA-Endorses-Extension-of-Therapeutic-Indications-for-Denosumab2

Biosimilar Filgrastim Safety Confirmed in Analysis

EP2006, a filgrastim biosimilar, produced safety results equivalent to those observed with referent filgrastim in a combined analysis of 2 Phase 3 breast cancer studies from the United States and Europe.

Read full article (External website)

Substantial Genomic Heterogeneity Characterises TNBC Molecular Subtypes

An integrative multiomic analysis identifies several candidate targets

Read full article (External website)

From Inspired to Involved: Why I Became a Breast Cancer Advocate

From Inspired to Involved: Why I Became a Breast Cancer Advocate

2018-03-15 22:00:00


English
TeMaya Eatmon, Voices on Cancer
March 15, 2018
TeMaya.Eatmon

TeMaya Eatmon’s friendship with a fellow breast cancer patient inspired her in ways she never imagined possible. Learn how heartbreaking loss led to a life-changing role as an advocate.

Source

Expert Discusses Optimizing CDK 4/6 Inhibitors in Breast Cancer

Expert Discusses Optimizing CDK 4/6 Inhibitors in Breast Cancer

2018-03-29 00:19:00

Reshma Mahtani, DO, discusses the tolerability of CDK 4/6 inhibitors for the treatment of patients with metastatic breast cancer.

Source

Mammograms and Older Women: Is It Ever Safe to Stop?

Mammograms and Older Women: Is It Ever Safe to Stop?

2018-03-27 21:00:00


English
March 27, 2018
Rachel.Freedman

Mammograms are a very important part of follow-up care in women with breast cancer. But what about older women? How long should they continue to receive mammograms?

Source

Trials Consider Role of Immunotherapy in Breast Cancer

Trials Consider Role of Immunotherapy in Breast Cancer

2018-03-29 10:16:32

Mixed results have occured in recent trials testing immuotherapy in patients with breast cancer. Checkpoint inhibitors have been used as monotherapy in a pair of trials, reporting lackluster overall response rates. When immunotherapy was paired with chemotherapy, on the other hand, it usually revealed better results, and gave signals that immunotherapies combined with targeted agents could work better than immunotherapy alone.

Source